Economic evaluation of adjuvant therapy with osimertinib in patients with early-stage non-small cell lung cancer and mutated EGFR.
Alejandro Vila PérezEmilio J Alegre-Del ReySilvia Fénix-CaballeroZuzana ŠpacírováPetra Rosado VarelaAntonio Olry de Labry LimaPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2023)
Taking into account a Spanish threshold of 24,000 €/QALY, the reduction in the acquisition cost of osimertinib will have to be greater than 10%, to obtain a cost-effective alternative.